BI Asset Management Fondsmaeglerselskab’s AbbVie ABBV Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.7M	Sell	241,796 -208,760	-46%	-$44.9M	0.48%	38
2026 Q1	$97.8M	Buy	450,556 +163,535	+57%	+$36.3M	1.02%	18
2025 Q4	$65.6M	Sell	287,021 -140,642	-33%	-$32M	0.58%	29
2025 Q3	$99M	Sell	427,663 -1,457	-0.3%	-$297K	0.89%	17
2025 Q2	$79.7M	Buy	429,120 +26,134	+6%	+$4.86M	0.78%	24
2025 Q1	$84.4M	Sell	402,986 -69,718	-15%	-$13.6M	0.95%	18
2024 Q4	$84M	Buy	472,704 +283,908	+150%	+$52.2M	0.89%	19
2024 Q3	$37.3M	Sell	188,796 -5,665	-3%	-$1.06M	0.65%	37
2024 Q2	$33.4M	Buy	194,461 +14,691	+8%	+$2.43M	0.55%	39
2024 Q1	$32.7M	Sell	179,770 -33,266	-16%	-$5.73M	0.62%	40
2023 Q4	$33M	Sell	213,036 -8,189	-4%	-$1.19M	0.7%	30
2023 Q3	$33M	Buy	221,225 +16,994	+8%	+$2.49M	0.77%	29
2023 Q2	$27.5M	Buy	204,231 +22,566	+12%	+$3.31M	0.65%	40
2023 Q1	$29M	Sell	181,665 -2,292	-1%	-$350K	0.77%	25
2022 Q4	$29.7M	Buy	183,957 +38,047	+26%	+$5.83M	0.79%	31
2022 Q3	$19.6M	Buy	145,910 +2,184	+2%	+$313K	1%	26
2022 Q2	$22M	Sell	143,726 -595	-0.4%	-$90.9K	0.94%	28
2022 Q1	$23.4M	Buy	144,321 +39,267	+37%	+$5.7M	0.9%	31
2021 Q4	$14.2M	Sell	105,054 -15,926	-13%	-$1.88M	0.52%	63
2021 Q3	$13.1M	Buy	120,980 +69,399	+135%	+$7.93M	0.49%	62
2021 Q2	$5.81M	Sell	51,581 -1,298	-2%	-$146K	0.22%	106
2021 Q1	$5.72M	Sell	52,879 -66,780	-56%	-$7.14M	0.23%	104
2020 Q4	$12.8M	Sell	119,659 -55,197	-32%	-$5.3M	0.56%	50
2020 Q3	$15.3M	Buy	174,856 +31,980	+22%	+$3.01M	0.7%	37
2020 Q2	$14M	Buy	142,876 +1,673	+1%	+$147K	0.72%	36
2020 Q1	$10.8M	Buy	141,203 +85,779	+155%	+$7.31M	0.64%	42
2019 Q4	$4.91M	Buy	55,424 +48,478	+698%	+$4.02M	0.23%	79
2019 Q3	$526K	Sell	6,946 -440	-6%	-$30.2K	0.03%	270
2019 Q2	$537K	Buy	+7,386	New	+$581K	0.03%	141

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's ABBV Position: Q2 2026 in Review

BI Asset Management Fondsmaeglerselskab reduced its AbbVie (ABBV) stake by 46% in Q2 2026, selling an estimated $44.9M and leaving 241,796 shares worth $60.7M. The position accounts for 0.48% of the portfolio, ranked #38.

BI Asset Management Fondsmaeglerselskab first reported a position in ABBV in Q2 2019 and has held it in 29 quarters since. The position peaked at $99M in Q3 2025. 3,306 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

BI Asset Management Fondsmaeglerselskab held 241,796 shares of AbbVie worth $60.7M as of Q2 2026.
BI Asset Management Fondsmaeglerselskab sold 208,760 AbbVie shares in Q2 2026, an estimated $44.9M.
AbbVie made up 0.48% of BI Asset Management Fondsmaeglerselskab's portfolio in Q2 2026, its #38 holding.
BI Asset Management Fondsmaeglerselskab first reported a position in AbbVie in Q2 2019 and has held it in 29 quarters since.
BI Asset Management Fondsmaeglerselskab's AbbVie position peaked at $99M in Q3 2025.
3,306 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2026, filed 10 Aug 2026.